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Abstract
Highly active antiretroviral therapy has remarkably improved quality of life of HIV-1-infected
patients. However, this treatment has been associated with the so-called lipodystrophic
syndrome, which conveys a number of adverse metabolic effects and morphological alter-
ations. Among them, lipoatrophy of subcutaneous fat in certain anatomical areas and hyper-
trophy of visceral depots are the most common. Less frequently, lipomatous enlargements
of subcutaneous fat at distinct anatomic areas occur. Lipomatous adipose tissue in the
dorso-cervical area (“buffalo hump”) has been associated with a partial white-to-brown phe-
notype transition and with increased cell proliferation, but, to date, lipomatous enlargements
arising in other parts of the body have not been characterized. In order to establish the main
molecular events associated with the appearance of lipomatosis in HIV-1 patients, we ana-
lyzed biopsies of lipomatous tissue from “buffalo hump” and from other anatomical areas in
patients, in comparison with healthy subcutaneous adipose tissue, using a marker gene
expression approach. Both buffalo-hump and non-buffalo-hump lipomatous adipose tissues
exhibited similar patterns of non-compromised adipogenesis, unaltered inflammation, non-
fibrotic phenotype and proliferative activity. Shorter telomere length, prelamin A accumula-
tion and SA-β-Gal induction, reminiscent of adipocyte senescence, were also common to
both types of lipomatous tissues. Buffalo hump biopsies showed expression of marker
genes of brown adipose tissue (e.g. UCP1) and, specifically, of “classical” brown adipocytes
(e.g. ZIC1) but not of beige/brite adipocytes. No such brown fat-related gene expression
occurred in lipomatous tissues at other anatomical sites. In conclusion, buffalo hump and
other subcutaneous adipose tissue enlargements from HIV-1-infected patients share a simi-
lar lipomatous character. However, a distorted induction of white-to-“classical brown adipo-
cyte” phenotype appears unique of dorso-cervical lipomatosis. Thus, the insults caused by
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HIV-1 viral infection and/or antiretroviral therapy leading to lipomatosis are acting in a loca-
tion- and adipocyte lineage-dependent manner.
Introduction
HIV-1 infection is currently treated using highly active anti-retroviral therapy (HAART),
which has dramatically improved patients’ life expectancy and quality. However, long-term
HAART in HIV-1 patients is associated with a number of adverse effects, including a form of
lipodystrophy designated HAART-associated lipodystrophy syndrome (HALS). Although
removal of the most toxic components of HAART cocktails has decreased the incidence of
HALS in recent years, the syndrome remains a frequent concern.
Altered adipose tissue distribution is a hallmark of HALS, with patients often showing lipoa-
trophy of subcutaneous adipose tissue in the face, arms, legs and buttocks; however, hypertro-
phy of visceral adipose tissue similar to abdominal obesity is also common [1,2]. Less
frequently, lipomatous alterations take place in HAART-treated patients, the most common of
which is a dorso-cervical accumulation, commonly referred to as “buffalo hump” (BH) [3].
Another site of prevalent lipomatous adipose enlargement is the pubic area [4], and a pattern
of accumulation of fat leading to circumferential enlargement of the neck, also called “bullfrog
neck”, has also been reported [5]. In addition, multiple reports have indicated the presence of
lipomas in HIV-1–treated patients scattered at different anatomical areas, such as the neck,
trunk, and limbs [4,6].
To date, molecular characterization of lipomatous tissue in HIV-1-infected patients has
been limited to the dorso-cervical BH fat. These studies have revealed a decrease in mitochon-
drial DNA (mtDNA) abundance in BH. However, this alteration is not likely to account for the
hypertrophic response of the dorso-cervical fat because other subcutaneous areas, which
exhibit the opposite lipoatrophic behavior, show similar levels of mtDNA depletion. Adipogen-
esis and inflammation, however, are not altered in BH; this is in contrast to the decreased
expression of adipogenesis marker genes and induction of pro-inflammatory genes in lipoa-
trophic areas of the same patients [7]. Several studies have shown that adipose tissues in BH
biopsies express uncoupling protein-1 (UCP1) [8,9] or 5’-deiodinase [10]—markers of brown
adipose tissue (BAT)—especially in samples obtained from substantially enlarged lipomatous
tissue requiring surgery.
With the recent use of positron emission tomography (PET) has come the recognition that
BAT in adult humans is present mainly in the cervical-supraclavicular region [11–14]. How-
ever, lipomatous BH appears not to be composed of fully functional brown adipocytes, and a
pathologically distorted adipocyte differentiation process that results in incomplete transition
from the white to brown adipocyte phenotype has been suggested. Among the observed
changes in BH cells, the acquisition of a highly proliferative status confirms the lipomatous fea-
tures of fat accumulation in BH [7,15].
Recent years have seen important advancements in our understanding of brown adipocyte
cell biology. Some brown adipocyte cells, now termed “classical” brown adipocytes, appear to
derive from precursor cells common to skeletal muscle, whereas other brown adipocytes,
referred to as beige or brite, appear to be more common to the white adipocyte cell lineage and,
in fact, may be interspersed in white adipose tissue depots [16,17]. Whereas all types of brown
adipocytes express UCP1, PPARGC1A (also known as PGC-1α) and PRDM16 (PR domain-
containing 16) genes, common markers of differentiation and thermogenic function, the
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expression levels of specific marker genes, such as ZIC1 (zinc finger protein of the cerebellum
1) for classical brown adipocytes allow the distinction of both types of brown adipocytes [18].
Human brown fat in adults (i.e., that present mainly in the cervical and sub-scapular region)
was initially considered to be composed mainly of beige/brite cells. However, recent data sug-
gests that there are also classical brown adipocyte-enriched areas in adult human thermogenic
adipose tissue [17,19–21].
Although lipoatrophic adipose tissue in HIV-1–associated lipodystrophy has been thor-
oughly studied [22–24], why some patients develop such opposing, hypertrophic events also in
the subcutaneous area remains a mystery, and no clear-cut indicators of specific antiretroviral
patterns or other mechanistic determinants have been identified. Moreover, it is unknown
whether the brown fat-like phenotype appears only in BH (i.e., at anatomical areas close to
those where brown fat is prevalent in adult humans) or is a general phenomenon of HIV-1–
associated lipomatosis everywhere in the body.
In the present study, we sought to identify the main molecular events associated with the
hypertrophic distortions that occur in adipose tissue in HIV-1 patients. To this end, we system-
atically characterized the molecular signature of lipomatosis in these patients by analyzing lipo-
matous samples at distinct anatomical regions.
Materials and Methods
Patients
HIV-1-infected patients were eligible if they had either lipomatous dorso-cervical enlargement
(BH) or lipomas from different anatomical locations (non-BH) that required surgical removal.
Subjects who were hospitalized or had a frank cognitive impairment on enrollment were not
eligible. Patients with opportunistic infections, acute hepatitis, liver insufficiency, neoplasms or
fever of undetermined origin were also excluded from the study. At the time of study enroll-
ment no patients were using any other drugs known to influence glucose metabolism or fat dis-
tribution, such as anabolic hormones or systemic corticosteroids, recombinant human growth
hormone, or appetite stimulants. Informed consent was obtained from the patients upon
enrollment. Biopsies of BH adipose tissue from 10 patients were analyzed upon surgical extrac-
tion. These samples were compared to non-BH lipomas removed from different anatomical
locations (two pubic, two sub-maxillary, one arm, three abdominal) in eight HIV-1–infected,
HAART-treated patients, as well as samples from 10 age-matched, healthy controls obtained
on occasion of minor dermatological surgical procedures from subcutaneous adipose tissue at
anatomical sites comparable to those in lipomatous samples, i.e., abdominal and upper (dorsal
and double chin) areas. To be eligible, controls did not have to meet any of the exclusion crite-
ria used for patients.
Demographic values, anti-retroviral treatment data and circulating parameters are shown in
Table 1. Age and body mass index (BMI) in patients and healthy controls were similar. Both
patient groups had higher levels of serum triglycerides and cholesterol than controls. There
were not significant differences in the cumulative time of treatment with the distinct types of
anti-retroviral drugs (nucleoside analog reverse transcriptase inhibitors, NRTIs; non-nucleo-
side reverse transcriptase inhibitors, NNRTIs; protease inhibitors, PIs) between the two patient
groups.
Tissue processing, RNA and DNA extraction
All extractions were performed with the written informed consent of patients, and were
approved by the Hospital de la Santa Creu i Sant Pau ethics committee. Once extracted, adipose
tissue biopsies were immediately frozen in liquid nitrogen and stored at -80°C. For RNA
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transcript analysis, frozen samples were fragmented by mechanical disruption and then
homogenized in RA-1 buffer (Macherey-Nagel, Düren, Germany) supplemented with 10% β-
mercaptoethanol. RNA was immediately isolated from the homogenate using a column affin-
ity-based methodology (NucleoSpin
1
RNA II; Macherey-Nagel). DNA was separated from the
tissue homogenate as a part of the protocol used for RNA extraction, dissolved in 70% ethanol,
and purified by phenol/chloroform extraction.
Gene expression analysis
cDNA was synthesized from 0.5 μg of total RNA using MultiScribe reverse transcriptase and
random hexamer primers (Applied Biosystems, Foster City, CA, USA). mRNA expression lev-
els were determined by quantitative real-time reverse transcription-polymerase chain reaction
(qRT-PCR) using TaqMan reagents and an Applied Biosystems 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems). Real-time PCR was performed in a final volume of 20 μL using Taq-
Man Universal PCR Master Mix, No AmpErase UNG reagent, and the following specific
primer probes (TaqMan Gene Expression Assays; Applied Biosystems) as detailed in S1 Table.
Cytochrome c oxidase subunit II (MT-CO2) mRNA was quantified using custom-designed
primers (forward, 5’-CAA ACC ACT TTC ACC GCT ACA C-3’; reverse, 5’-GAC GAT GGG
CAT GAA ACT GT-3’) and FAM-labeled probe (5’-AAA TCT GTG GAG CAA ACC-3’)
obtained from Applied Biosystems (Custom TaqMan Gene Expression Assays). mRNA levels
of the genes of interest, normalized to that of the reference control (18S ribosomal RNA), were
calculated using the comparative 2-ΔΔCT method.
Protein expression analysis
For Western blot analysis of protein expression, fragments of previously disrupted adipose tis-
sue were homogenized in cold buffer consisting of 10 mmolL-1 HEPES (pH 7.5), 5 mmolL-1
ethylenediamine tetraacetic acid, 5 mmolL-1 dithiothreitol, and 5 mmolL-1 MgCl2 supple-
mented with protease inhibitor (Complete-mini; Roche, Sant Cugat del Vallés, Spain). The
Table 1. Demographic values, treatment data and biochemical parameters in controls and HIV-1-infected patients bearing BH and NBL lipomas.
HIV-1-infected patients
Control (n = 10) Buffalo hump (n = 10) Non-buffalo hump lipomas (n = 8)
Age (years) 57.4 ± 3.6 55.8 ± 1.4 54.2 ± 2.0
Sex (n) 6 7 5
BMI (kgm-2) 26.1 ± 1.2 25.6 ± 2.6 25.3 ± 1.6
Glucose (mmolL-1) 3.2 ± 0.3 3.7 ± 0.1 4.5 ± 0.8
Triglycerides (mmolL-1) 1.2 ± 0.3 3.9 ± 0.5* 3.1 ± 0.6*
Cholesterol (mmolL-1) 3.1 ± 0.6 5.6 ± 0.1* 6.2 ± 0.4*
Clinical lipodystrophy No Yes Yes
Time since HIV-1 infection (months) - 167 ± 18 177 ± 24
Cumulative time (months) on:
NRTIs - 140 ± 22 152 ± 20
NNRTIs - 25 ± 2 32 ± 9
PIs - 30 ± 12 38 ± 16
CD4+ lymphocytes (cellsμL-1) - 549 ± 74 445 ± 84
Values are expressed as means ± SEM. Statistical differences between controls and both groups of lipodystrophic patients are shown as * whenever
signiﬁcant (p<0.05).
doi:10.1371/journal.pone.0136571.t001
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protein concentration in each sample was determined by the Bradford method, with detection
of absorbance at 595 nm absorbance using a Shimadzu UV 160-A spectrophotometer. Homog-
enates containing equal amounts of protein (40 μg) were brought to a total volume of 35 μL
with bidistilled water, mixed with 1/5 volume loading buffer (10% sodium dodecyl sulfate
[SDS], 10% β-mercaptoethanol, 0.5 M Tris pH 6.8, 50% glycerol, 0.5% bromophenol blue) and
incubated at 95°C for 5 min. Proteins in samples were then resolved on SDS-containing 10%–
12% polyacrylamide gels and transferred to Immobilon-P nitrocellulose membranes (Milli-
pore, Billerica, MA, USA) using a Mini Trans-Blot kit (Bio-Rad Laboratories, Hercules, CA,
USA). Blots were incubated with primary antibodies against PPARγ (sc-1984X), LPL (sc-
73646), GLUT4 (sc-7938), PCNA (sc-25280), adiponectin (sc-26497) and lamin A/lamin C/
prelamin A (sc-6215), obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA);
β2-microglobulin (P0163), obtained from Dako Cytomation (Glostrup, Denmark); cytochrome
c oxidase subunit II (12C4), obtained from Molecular Probes (Eugene, OR, USA); p53 (2570S)
from Cell Signaling (Danvers, MA, USA) or β-actin (A5441), obtained from Sigma Chemical
Co. (St Louis, MO, USA). After incubating with primary antibodies, blots were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (BioRad), donkey anti-rabbit
IgG (Jackson Immunoresearch, West Grove, PA, USA) or rabbit anti-goat IgG (Sigma), as
appropriate. Immunoreactive proteins were detected using a Millipore Immobilon Western
chemiluminescent HRP system (Millipore) and a Fujifilm ImageRecorder LAS-3000 detection
device (Fujifilm, Tokyo, Japan). The optical density of each band was quantified using the Mul-
tiGauge 3.0 software suite (Fujifilm).
mtDNA quantification
Total DNA isolated from tissue samples was purified by phenol/chloroform extraction, as indi-
cated above, and the relative abundance of mtDNA was assessed by real-time PCR as previ-
ously described [7]. mtDNA levels were expressed as the amount of the mitochondrial gene
MT-CYB (cytochrome B) relative to the nuclear, intronless, single-copy gene CEBPA (CCAAT/
enhancer binding protein alpha). The TaqMan probes used to determineMT-CYB and CEBPA
expression are shown in S1 Table.
Telomere relative length quantification
Telomere length was assessed by real-time PCR essentially as described previously [25]. Briefly,
PCR was performed using 35 ng of total DNA (PCR template) isolated from tissue homoge-
nates in a reaction containing 10 μL of 2x SYBR Green Master Mix reagent (Applied Biosys-
tems) and 100 nM of specific primers (Sigma) for telomere repeats (Tel) or the single-copy
housekeeping gene 36B4 (acidic ribosomal phosphoprotein P0) in a final volume of 20 μL. The
following primer pairs were used: Tel, 5’-CGG TTT GTT TGG GTT TGG GTT TGG GTT
TGG GTT TGG GTT-3’ (forward) and 5’-GGC TTG CCT TAC CCT TAC CCT TAC CCT
TAC CCT TAC CCT-3’ (reverse); and 36B4, 5’-GCA AGT GGG AAG GTG TAA TCC-3’ (for-
ward) and 5’-ATT CTA TCA TCA ACG GGT ACA A-3’ (reverse). CT values were obtained
for both Tel and 36B4 in each sample. Relative telomere abundance was quantified as the Tel/
36B4 ratio using the comparative 2-ΔΔCT method.
Statistical analysis
Results are expressed as means ± SEM. Statistical comparisons between groups were performed
using a non-parametric analysis (Mann-Whitney U test). Statistical differences were consid-
ered significant for p-values< 0.05.
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Results
The levels of transcripts for marker genes related to adipogenesis and adipose function (PPAR-
γ, LPL and AdipoQ), inflammation (TNFα), macrophage infiltration (CD68), mitochondrial
toxicity (MT-CO2), and fibrosis (COL1A2) were determined in lipomatous and healthy con-
trol adipose tissues (Fig 1). Lipomatous adipose tissue data were analyzed separately for BH
samples and non-BH lipomatous tissue (NBL), as described in Materials and Methods.
Transcript levels for adipogenesis marker genes, including peroxisome proliferator-acti-
vated receptor (PPAR)-γ, the master regulator of adipose differentiation, LPL (lipoprotein
lipase), the enzyme responsible for fatty acid uptake and fat accretion in adipose tissue, and
adiponectin, a main adipokine, were unaltered in BH compared with healthy subcutaneous
adipose tissue. However, each of these three gene transcripts was systematically up-regulated in
NBL from HIV-1–infected patients. Tumor necrosis factor (TNF)-α, a marker of inflamma-
tion, and CD68, a macrophage infiltration marker, were not altered in any of the adipose tissue
sample groups analyzed. Expression of the mtDNA-encoded transcriptMT-CO2 was altered
only in NBL samples, where it was significantly increased. Expression of the fibrosis marker
COL1A2 (collagen type I alpha 2) trended lower in BH and NBL samples relative to controls,
but only the reduction in BH reached statistical significance.
Given that mitochondrial toxicity, specifically mtDNA depletion, is a relevant feature of co-
morbidities present in HIV-1–infected patients undergoing treatment, we next quantified
mtDNA levels. These analyses revealed that mtDNA levels were significantly reduced in BH
samples relative to healthy controls, but were unaltered in NBL (Fig 1B).
We next extended our study to an analysis of marker expression at the protein level (Fig 2A
and 2B). Unlike transcripts, protein levels of PPARγ, LPL and adiponectin as well as those of
the glucose transporter GLUT4, another protein associated with adipogenesis, were not signifi-
cantly different between BH or NBL samples and controls. The abundance of β2-microglobulin,
an indicator of inflammation, was also unaltered. Levels of the mtDNA-encoded protein
MT-CO2 were significantly reduced relative to controls to a similar extent in both BH and
NBL samples. An analysis of the expression of the proliferation marker, PCNA [26], showed a
substantial increase in PCNA protein levels in BH and NBL relative to healthy subcutaneous
adipose tissue, with the extent of the increase being similar for the two types of lipomatous
tissue.
Considering the differences found, and taking into account the distinct anatomical location
of NBL samples, we analyzed the gene expression and protein data by separately pooling data
from samples taken from upper and lower body areas (using the waist as the dividing line). As
shown in S2 Table, the only significant anatomical site-dependent changes observed were
minor differences forMT-CO2 and adiponectin expression in both NBL patients and healthy
controls.
Accelerated ageing is often considered to be associated with co-morbidities that appear in
HIV-1 patients, and telomere length in adipose tissue has been proposed as a marker of senes-
cence and ageing-related phenomena that occur in fat under pathological conditions such as
obesity [27]. We found that telomere length was profoundly decreased in both BH and NBL
relative to healthy controls, with no differences between the two types of lipomatous tissue (Fig
3A). Notably, telomere length in lipoatrophic, non-lipomatous, adipose tissue from HIV-1–
infected patients was not altered compared with that in healthy controls (data not shown).
Determination of the expression of the GLB1 gene, encoding SA-β-Gal [28], a marker of senes-
cence, indicated a significant increase in both BH and NBL relative to controls (Fig 3B). We
also measured p53 levels as a further marker of senescence but, in this case, no significant dif-
ferences were found (data not shown).
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Several partial lipodystrophy syndromes of genetic origin, sometimes associated with local
lipomatous phenomena, are caused by alterations in the synthesis of lamin A protein that
results in accumulation of the unprocessed prelamin A form in lipomatous tissue [29]. This
phenomenon has been related to accelerated ageing [30]. We detected this high-molecular-
weight, unprocessed form of prelamin A in BH and NBL samples, but found only weak expres-
sion in control adipose tissue, thus the prelamin A/lamin A ratio was increased in both BH and
NBL relative to healthy control adipose tissue. (Fig 3C).
Finally, we analyzed the expression of brown-versus-white adipose tissue marker genes (Fig
4A). Expression of UCP1 and PPARGC1AmRNA was significantly higher in BH, but not NBL,
compared with healthy control adipose tissue, whereas PRDM16 transcript levels were
unchanged. Expression of the β3-adrenergic receptor, on the other hand, was dramatically
repressed in BH, but not in NBL. We further analyzed the expression of marker genes recently
proposed to distinguish between classical or developmentally programmed brown adipose tis-
sue and inducible or beige/brite brown adipose tissue [31,32] (Fig 4B–4D). ZIC1mRNA, which
was highly expressed in BH, showed negligible and very low expression in control adipose tis-
sue and NBL, respectively. In contrast, EBF3 (early B-cell factor 3) and FBXO31 (F-box only
protein 31), two other marker genes proposed to distinguish between the two types of brown
fat, were upregulated in common in BH and NBL compared with controls. An analysis genes
proposed in some studies to be markers of the beige/brite type of fat showed that expression of
TBX1 (T-box 1) was decreased in both enlarged BH and NBL sites compared with control fat,
whereas TMEM26 and TNFRSF9/CD137 (tumor necrosis factor receptor superfamily, member
9) expression were not different among adipose tissues. It has been proposed that expression of
HOXC8 (homeobox C8) andHOXC9 (homeobox C9) genes is preferentially associated with
the white adipocyte phenotype relative to either the classical or beige/brite brown phenotype.
We found that HOXC9 expression was dramatically reduced in BH but unaltered in NBL rela-
tive to controls, whereas HOXC8 was significantly increased in NBL.
Fig 1. Expression of mRNA for various marker genes andmtDNA levels in BH and non-BH lipomas from HIV-1–infected, HAART-treated patients
and healthy control subcutaneous adipose tissue. A) Relative mRNA levels of the indicated markers of adipogenesis and adipocyte function,
mitochondrial function, inflammation, and fibrosis were determined by qRT-PCR. Means ± SEM, expressed as ratios relative to 18S rRNA, are shown for
each target mRNA. B) mtDNA data are presented as means ± SEM, expressed as a ratio units between the mitochondrial geneMTCYB and the single-copy
nuclear gene CEBPA levels (*p<0.05, lipomas vs. healthy control; #p<0.05, NBL vs. BH). (*p<0.05, **p<0.01 and ***p<0.001, lipoma vs. healthy
subcutaneous adipose tissue; #p<0.05, ##p<0.01, NBL vs BH). Means correspond to 10 (C, BH) and 8 (NBL) samples.
doi:10.1371/journal.pone.0136571.g001
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Discussion
Dorso-cervical adipose accumulation, often referred as buffalo hump, is an alteration that
occurs with a certain frequency in HIV-1 patients undergoing antiretroviral treatment, but
attempts to associate it with specific patterns of treatment or other variables have been unsuc-
cessful. There have been recent reports of the appearance of BH even in patients undergoing
newer drug treatment regimens (e.g., raltegravir-based) with low toxicity towards adipose func-
tion and metabolism [33]. In addition to BH, adipose enlargements randomly occur in patients
at other sites of subcutaneous adipose tissue, with the highest frequency observed in the neck
[5] and pubic [4] regions. Previous studies have shown that expression of adipogenesis and
inflammation marker genes is unaltered in BH in HIV-1–infected, HAART-treated patients;
Fig 2. Expression of protein for variousmarker genes in BH and non-BH lipomas from HIV-1–infected, HAART-treated patients and healthy control
subcutaneous adipose tissue. A) Relative protein levels of the indicated markers of adipogenesis and adipocyte function, mitochondrial function,
inflammation, and cell proliferation were determined by densitometric analysis of Western blots. Means ± SEM of 10 (C, BH) and 8 (NBL) samples expressed
as ratios of the optical density of each band corrected for total protein level, are shown for each protein (*p<0.05, **p<0.01 and, lipomas vs. healthy
subcutaneous adipose tissue; #p<0.05, ##p<0.01 and ###p<0.001, NBL vs. BH).B) Representative Western blot bands for selected genes of each
functional group in panel A for controls (C), BH, and NBL. Each sample corresponds to an individual from each group. β-actin was used a loading control. The
molecular weight of each specific immunoreactive signal is shown at right. ADIPOQ, adiponectin; MT_COII, mitochondrial DNA-encoded subunit II of
cytochrome c oxidase.
doi:10.1371/journal.pone.0136571.g002
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this contrasts with the repressed adipogenesis and enhanced local inflammation observed in
lipoatrophic subcutaneous fat [7]. We found that non-BH enlarged adipose depots apart from
BH presented similar patterns of unaltered adipogenesis and inflammation, at least at the pro-
tein level. This finding confirms that hypertrophy of subcutaneous fat is associated with protec-
tion from the induction of pro-inflammatory responses that are known to take place at sites
prone to lipoatrophy in HIV-1 patients. A feature of NBL that distinguishes it from BH is that
protein markers of adipogenesis (LPL, PPARγ, adiponectin) are unchanged despite enhanced
expression of the corresponding transcripts. The mechanisms underlying this discordance are
unknown, but the fact that post-transcriptional and post-translational mechanisms are known
to be relevant for determining LPL and PPAR-γ protein levels in adipose tissues should be
taken into account [34,35]. Discordances between changes in adiponectin transcript and pro-
tein levels occur in subcutaneous adipose tissue from HIV-1-infected patients [36,37]. More-
over, as a secreted protein, adiponectin steady-state levels in cells may not change despite
concerted alterations in synthesis and output, a fact that may also help explain this
observation.
Indeed, our current findings support the lipomatous character of these other subcutaneous
adipose tissue enlargements that appear locally in HIV-1 patients (i.e., pubic area, circumferen-
tial neck), as previously reported for BH [7]. The increased expression of PCNA, a bona fide
marker of cell proliferation, confirms the activated cell-cycle status in the distinct, enlarged
Fig 3. Relative telomere length, expression ofGLB1 (SA-β galactosidase) and prelamin A/lamin A ratio in adipose tissue from BH and NBL lipomas
from HIV-1–-infected, HAART-treated individuals and in subcutaneous adipose tissue from healthy controls. A)Relative telomere lengths are
presented as means ± SEM, expressed as a ratio of arbitrary fluorescence units for telomere repeats (Tel) to the single-copy nuclear gene 36B4 (*p<0.05,
lipomas vs. healthy controls). B) Relative mRNA levels of SA-β-Galactosidase. Means ± SEM, expressed as ratios relative to 18S rRNA, are shown. C)
Prelamin A/lamin A ratio are presented as means ± SEM of the relative densitometric analysis of western blots (right), representative western blot bands for
lamin A and prelamin A are shown (left). The bands for both processed lamin and unprocessed prelamin are indicated with arrows. Means correspond to 10
(C, BH) and 8 (NBL) samples.
doi:10.1371/journal.pone.0136571.g003
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Fig 4. Expression of mRNA for brown adipocyte-associated genes and specific lineagemarkers of different classes of adipocytes in adipose
tissue from BH and NBL lipomas from HIV-1–infected, HAART-treated individuals and in subcutaneous adipose tissue from healthy controls (C).
Relative mRNA levels were determined by qRT-PCR. Means ± SEM of 10 (C, BH) and 8 (NBL) samples, expressed as ratios relative to 18S rRNA, are
shown for each target mRNA (*p<0.05, **p<0.01 and ***p<0.001, lipomas vs. healthy subcutaneous adipose tissue; #p<0.05, ##p<0.01 and ###p<0.001,
NBL vs. BH lipomas).A) Brown adipocyte-associated genes.B-D) Specific putative lineage markers of different types of adipocytes.
doi:10.1371/journal.pone.0136571.g004
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adipose tissue depots analyzed here. This means that lipid accumulation and hypertrophy
alone are not sufficient to explain the adipose enlargement, suggesting that hyperplasia of adi-
pose tissue contributes to adipose depot overgrowth, both in BH and at distinct anatomical
sites. Fibrosis, a feature usually found in rapidly proliferating adipose depots that leads to
inflammation [38], was not increased, at least not at the transcriptional level. Notably, we
found a dramatic reduction in DNA telomere length in both BH and non-BH enlarged adipose
depots relative to control healthy adipose tissue, finding that strongly supports the lipomatous
character of these adipose sites. Shortening of telomeres is a consequence of tissues having
experienced high rates of cell replication, as has previously been reported for adipose depots in
obese patients [27,39]. As a non-malignant tumorigenic process, lipomatosis maintains telo-
mere shortening with cell division [40]; this contrasts with malignant tumorigenesis, which
evades telomere shorting through activation of telomerase [39,41]. To our knowledge, our cur-
rent findings represent the first data on telomere length as a marker of cellular behavior in fat
depots from HIV-1–infected patients.
The common lipomatous character of BH and non-BH adipose enlargements is also evi-
denced by the accumulation of the toxic, non-processed form of lamin A, a phenomenon previ-
ously reported to take place not only in genetically-determined lipomatosis [29,42] but also in
BH from HIV-1–infected, HAART-treated patients [9], as well as in the lipoatrophic areas of
these individuals. Our results, taken together with previous observations [43,44], suggest that
lipomatosis in HIV-1 patients reflects an increased aging phenotype, as evidenced by prelamin
A accumulation, telomere length reduction and enhanced expression of SA-β-Galactosidase. In
contrast to lipoatrophic areas, hyperproliferative lipomas would therefore compensate for cell
death with accelerated precursor cell turnover, thus growing in size.
Our current findings confirm previous reports indicating partial acquisition of a brown adi-
pose tissue molecular signature in BH. Our demonstration of increased expression of UCP1 is
in accord with previous findings [7–9]. The partial acquisition of a brown adipose tissue phe-
notype is further underscored by the strong repression of β3-adrenoreceptor mRNA expression
—a common finding in thermogenically activated brown adipose tissue in experimental mod-
els [45]. However, non-BH lipomatous sites did not show a remarkable expression of UCP1.
Even when non-BH samples from circumferential neck enlarged adipose tissue close to sites
where physiological brown adipose tissue is known to be present were analyzed separately,
UCP1 expression was negligible. These findings indicate that the acquisition of a partial brown
fat-type molecular signature is a specific feature of BH that is not shared by lipomas at other
anatomical sites in HIV-1 patients.
This study represents the first use of marker genes proposed to allow the distinction
between beige/brite and classical brown fat to characterize the brown fat-like features of BH.
Our finding of very high expression of ZIC1, possibly the most specific, and best accepted,
marker of classical, non-beige/brite, brown adipocytes [19–21,46], indicates that abnormal
classical brown adipogenesis underlies the BH phenotype.
The suppressed expression of HOXC9, a proposed marker of the white-versus-brown phe-
notype [19,20], specifically in BH further supports the shift from white to brown adipogenesis
in BH. The information obtained regarding a putative beige/brite phenotype was less conclu-
sive, as only some increase in NBL versus BH expression was found. In fact, the determination
of classical brown-versus-beige/brite phenotype made on the basis of marker gene expression
analysis should be considered with caution, considering how recently these markers, the lack of
unanimous agreement on their use and scarce validation in humans tissue of data obtained in
rodents [46–48]. In this context, some studies have reported that TMEM26 is preferentially
found in human BAT [17,32] whereas others have reported no differences between BAT and
WAT [19,20]. The value of TNFRSF9 (CD137) as bona-fide beige marker has also been
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questioned, and a recent comprehensive compilation of available data suggested that, whereas
ZIC1 is emerging as a bona-fide marker of “classical” BAT in humans, the validity of beige/
briter markers in human adipose tissues is less compelling [46].
Overall, our findings strongly support the conclusion that a brown fat-like phenotype
related to the classical brown adipocyte cell lineage is specifically induced in HIV-1–associated
BH but not in lipomas at other anatomical sites. Recent reports have claimed that adipocytes of
the classical brown type are present in human adults [19,20]; thus, it is likely that a specific dis-
tortion of this cell type elicited by HIV-1 infection and/or antiretroviral treatment underlies
the etiopathology of BH lipomatosis.
The present study has obvious limitation: the relative scarcity of samples in this type of stud-
ies, the anatomical variability of NBL location, the impossibility to perform the study in distinct
lipomas from the same indivdual, and the single molecular approach followed. We were none-
theless able to conclude that BH and adipose enlargements that occur at different anatomical
sites in HIV-1–infected, HAART-treated patients share a similar lipomatous character and the
absence of a local pro-inflammatory status. However, only BH exhibited a distortion in the
brown-to-white molecular signature that appears to involve the classical brown adipocyte cell
lineage. Overall, the present data provide evidence that HIV-1 infection and antiretroviral tox-
icity-mediated alterations in adipose tissue plasticity may differentially impact distinct anatom-
ical sites according to a distinct molecular signature of affected tissue areas. Although our data
allow few conclusions to be reached regarding prevention or treatment of this alteration, they
suggest that proposals to promote brown adipose tissue activation as a tool for improving the
metabolic syndrome, especially as it applies to HIV-1–infected patients, should therefore be
considered with caution in the future.
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